Big pharmas and biotechs alike need to consider the impact of reimbursement on a product's market opportunity when structuring deals, given the growing influence of payers, but industry execs grappled with how to do this at the BIO-Windhover Pharmaceutical Strategic Outlook conference in New York City on Feb. 24.
King Pharmaceuticals touts script growth for its extended release morphine sulfate formulation Embeda while awaiting an Okay from FDA's Division of Drug Marketing, Advertising and Communications on marketing materials for the drug, during a year-end earnings call to investors Feb. 25.
